Recently published research from Global Markets Direct, "Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2012", is now available at Fast Market Research

Boston, MA -- (SBWire) -- 10/20/2012 --Global Market Direct's pharmaceuticals report, "Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2012" provides data on the Eiger BioPharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Eiger BioPharmaceuticals, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Eiger BioPharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents

Scope

- Eiger BioPharmaceuticals, Inc. - Brief Eiger BioPharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Eiger BioPharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Eiger BioPharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Eiger BioPharmaceuticals, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to Get this Report

- Evaluate Eiger BioPharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Eiger BioPharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Eiger BioPharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Eiger BioPharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Eiger BioPharmaceuticals, Inc. and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Keryx Biopharmaceuticals, Inc. - Product Pipeline Review - 2012
- Morria Biopharmaceuticals Plc - Product Pipeline Review - 2012
- SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2012
- RegeneRx Biopharmaceuticals, Inc. - Product Pipeline Review - 2012
- Accentia Biopharmaceuticals, Inc. - Product Pipeline Review - 2012
- Nabi Biopharmaceuticals - Product Pipeline Review - 2012
- AEterna Zentaris Inc. - Product Pipeline Review - 2012
- Sigma-Tau S.p.A. - Product Pipeline Review - 2012
- Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2012
- Hemophilia A - Pipeline Review, H2 2012